Chances of Recovery From Rare Brain Tumour Influenced by Factors Including Age and Weight

Study involving researchers from Karl Landsteiner University of Health Sciences in Krems identifies factors which affect postoperative progression of rare brain tumour in adults.

Krems (Austria), September 30th, 2020 – Age and body mass index are among the factors that have a significant impact on the clinical course of a particular type of brain tumour, known as pilocytic astrocytoma, in adult patients. This was the main finding of one of the world’s largest studies on this topic, which has now been published in an international journal. The study was conducted by the Medical University of Vienna (MedUni Vienna) in conjunction with researchers from Karl Landsteiner University of Health Sciences in Krems (KL Krems) and partners from Germany. The researchers showed that pilocytic astrocytoma has very specific characteristics when it affects adults – recurrence or progression occurs almost twice as frequently following operative resection in comparison with child sufferers. A body mass index of over 23 also led to more frequent recurrence of the tumour. In future, these new insights could result in more accurate prognosis for adult patients, and enable corresponding optimisation of treatment approaches.

Brain tumours come in many different forms. There are currently more than 120 recognised types, some of which are classified as benign, since they grow slowly and barely spread to other parts of the brain. Pilocytic astrocytoma (PA) – the most common brain tumour among children – is included in this category. In many cases, operative removal is an effective form of treatment, and the ten-year overall survival rate among child patients is more than 90%. This kind of brain tumour is much less common in adults, meaning that data on its progression is in short supply. But this has now changed thanks to a new study, one of the largest conducted on this topic anywhere in the world. The findings were published in the Journal of Neuro-Oncology.

Identifying Key Factors
“Data were evaluated from 46 patients aged between 19 and 74 who had undergone operative resection of the brain tumour,” explained Prof. Stefan Oberndorfer, head of the Clinical Department of Neurology at St. Pölten University Hospital, Karl Landsteiner University of Health Sciences. “We clearly identified two factors – among others – that influence the clinical course after the operation: age and body mass index, or BMI”

Indeed, the findings show that compared with children, the tumour recurred or continued growing in almost twice as many cases among adult sufferers (19.6% vs. 10%) following the operation. The median follow-up period was 53 months. More detailed analysis of the results revealed a notable increase in the chances of further tumour growth from the age of 40.


BMI Plays Key Role
Headed by Prof. Anna Sophie Berghoff at the Medical University of Vienna, the research team subsequently concluded that a patient’s BMI – a function of a person’s height and weight – has a major impact on the clinical progression of the condition following operative removal of the tumour. According to Prof. Oberndorfer: “On average, the patients had a BMI of 22.8 when they were diagnosed. But if the BMI was higher, the tumour recurred or started growing again far more quickly, and the average survival rate was also shorter.” Little is known about the connection between a higher BMI and the poorer clinical prognosis this leads to. However, it is presumed that physiological consequences such as a high blood sugar level, insulin resistance or the increased release of fatty acids into the blood could influence certain factors related to tumour growth.

MedUni Vienna’s neurology database provided the basis for the study. It contained anonymised data from 46 patients who were diagnosed with and received treatment for PA between 2000 and 2018. The data were evaluated and analysed by staff at the Division of Oncology at MedUni Vienna, in collaboration with the St Pölten University Hospital, Department Neurology, as well as researchers from Heidelberg University and the German Cancer Research Center. The findings will support efforts to identify more aggressive courses of this rare condition at an earlier stage, and adapt and improve the treatment these patients receive.

Original publication: Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. M. J. Mair, A. Wöhrer, J. Furtner, A. Simonovska, B. Kiesel, S. Oberndorfer, K. Ungersböck, C. Marosi, F. Sahm, J. A. Hainfellner, K. Rössler, M. Preusser1, G. Widhalm., A. S. Berghoff, Journal of Neuro-Oncology (2020) 148:187–198 https://doi.org/10.1007/s11060-020-03513-9

Scientific Contact
Prim. Assoc. Prof. Dr. Stefan Oberndorfer
Department of Neurology
University Hospital St.Pölten
Karl Landsteiner University of Health Sciences
Dr.-Karl-Dorrek-Straße 30 
3500 Krems / Austria
T +43 / 43 2742 9004-13060
E stefan.oberndorfer@stpoelten.lknoe.at
W http://www.stpoelten.lknoe.at

Karl Landsteiner University of Health Sciences
Eva-Maria Gruber
Communication, PR & Marketing (Head)
Dr.-Karl-Dorrek-Straße 30
3500 Krems / Austria
T +43 2732 72090 231
M +43 664 5056211
E evamaria.gruber@kl.ac.at
W http://www.kl.ac.at/

Copy Editing & Distribution
PR&D – Public Relations for Research & Education
Dr. Barbara Bauder
Mariannengasse 8
1090 Vienna / Austria
T +43 1 505 70 44
M +43 664 1576350
E bauder@prd.at
W http://www.prd.at/

About Karl Landsteiner University of Health Sciences
Karl Landsteiner University of Health Sciences (KL) is a pioneer for innovation in medical and health sciences education and research, and a catalyst for groundbreaking work which will benefit society at large. Research at KL focuses on niche fields in bridge disciplines such as molecular oncology and hematology, biomedical engineering, psychology and psychodynamics, as well as topics including water quality and related health issues. Study programmes include health sciences, human medicine, psychology, psychotherapy and counselling and have full European recognition. A network of university hospitals in St. Pölten, Krems, and Tulln provides students with quality-assured, research-led education; it. It enables them to do internationally- recognized top-class clinical and translational research that is recognised worldwide. Karl Landsteiner University received accreditation by the Agency for Quality Assurance and Accreditation Austria (AQ Austria) in 2013.

This release was published on openPR.